Diaclone's Scientific History

Quality Products Developed on a History of Scientific Expertise

The oustanding Diaclone product quality and scientific reputation is built on cutting edge therapeutic antibody collaborations within the pharmaceutical industry. The same level of quality is the hallmark of the entire Diaclone product range maintaining our reputation as an established centre of excellence for monoclonal antibody research and development. From monoclonal antibodies through to assay development our expertise is every present ensuring consistent high product quality.

  • 1986: Founded in collaboration with the Regional Bloodbank in Besancon to develop monoclonal antibodies for in vitro bone marrow depletion prior to autologous transplantation.
  • 1988: First in-vivo treatment of graft versus host disease using a Diaclone Monoclonal Antibody against CD25
  • 1990: Clinical trials using Diaclone IL-6 Monoclonal Antibody as a potential therapy against multiple disease states initiated
  • 1991: Diaclone developed its first generation of Immunoassay kits and extended the range of commercially available antibodies
  • 1993: Following these early trials and immunoassay developments Diaclone successfully presented these high quality monoclonal antibodies in its first product catalogue
  • 1994: New Diaclone antibodies continue to be investigated in clinical trials for their potential therapeutic applications
  • Established skills allow development of monoclonal antibodies to distinguish between soluble and membrane bound receptors
  • Antibodies developed to discriminate between proteins that share common chains and proteins where the difference between human and mouse is as little as a single amino acid
  • Continued investigation of our antibodies for therapeutic potential in many conditions including Multiple Myeloma (anti-CD138, 2000) and RA (anti-CD4, 2001)
  • 2012: Diaclone’s Current Catalogue has over 490 Monoclonal Antibody products and over 950 immunoassay products (Including ELISA, ELISpot and Multiplex)
  • 2012: Excellent on-going relationship with the Besancon Regional Bloodbank provides unlimited access to white blood cells, advice and expertise
  • 2012: We Remain in Besancon with 25 dedicated and experienced staff, Dr Philippe Dulieu CEO. Now part of the Biotech Investissement group and a sister company of RD Biotech.